Delving into the Latest Updates on Fresenius Kabi with Synapse

Overview

The study objective is aimed to describe all country, site, investigator and patient variables that lead to treatment persistence for at least 12 months among patients with rheumatologic and intestinal chronic inflammatory diseases who were switched to FK adalimumab, in order to develop a model to predict persistence at 12 months.

Start Date30 Apr 2022

Sponsor / Collaborator

Fresenius Kabi

NCT04807478

/ WithdrawnNot Applicable

A Multicenter, Prospective, Controlled, Longitudinal-Cohort Study Assessing the Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

This study will demonstrate Short-, mid-, and long-term safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population

Start Date01 Apr 2022

Sponsor / Collaborator

Fresenius Kabi

100 Clinical Results associated with Fresenius Kabi

Login to view more data

0 Patents (Medical) associated with Fresenius Kabi

Login to view more data

9

Literatures (Medical) associated with Fresenius Kabi

01 Oct 2023·Transfusion

P‐CB‐13 | In Vitro Evaluation of Cytokine Reduction Using the Smart Wash with the CATSMART Device

Author: Sheth, L. ; Karpiel, A.

01 Jan 2015·Branched Chain Amino Acids in Clinical Nutrition

The Branched Chain Amino Acids in the Context of Other Amino Acids in Traumatic Brain Injury

Author: Melanie K. Bothe ; John F. Stover

Neurotrauma initiates a cascade of changescausing subsequent delayed cellulardamage. Within this cascade, impaired cerebral blood flow leads to inadequate oxygen supply followed by disturbed brain metabolism which is further exacerbated by excitotoxicity leading to cell death as well as neuroinflammation. Clinical management of traumatic brain injury (TBI) focuses on prevention or reduction of secondary damage.In this context, nutrition and specifically amino acids are given to TBI patients based on recommendations for critically ill patients. Unfortunately, potential variations and specific requirements for TBI are not considered. In patients with brain injury amino acid solutions couldinduce excitotoxicity and increase brain damage by providing precursors of neurotransmitters. At the same time, specific amino acids might provide beneficial effects in certain phases of TBI by ameliorating vasogenic and cytotoxic edema or improvingcerebral oxygen consumption. The dynamic plasma amino acid profile following TBI shows a complex pattern strongly influenced by the post-injury phase. In this chapter, the potential effects of branched chain and aromatic amino acids following TBI will be discussed.

01 Jan 2004·Annals of Nutrition and MetabolismQ4 · MEDICINE

Elimination and Tolerance of a New Parenteral Lipid Emulsion (SMOF) – A Double-Blind Cross-Over Study in Healthy Male Volunteers

Q4 · MEDICINE

Article

Author: Schlotzer, Ewald ; Kanning, Ulrike

Aims: The objective of this phase I study was to investigate plasma elimination and tolerance of a new lipid emulsion based on soybean oil, medium chain triglycerides (MCT), olive oil and fish oil (SMOF). Methods: In a double-blind, randomized, cross-over study, 12 healthy male subjects received SMOF 20% and a standard soybean oil emulsion (Lipovenoes® 20%, both Fresenius Kabi). Lipid emulsions were infused at a rate of 0.125 g fat/kg body weight/h over 6 h. Before, during and up to 24 h after infusion, lipid metabolism parameters and numerous clinical, chemical and hematological parameters, vital signs and local tolerance were determined. Results: Infusion of SMOF induced a less marked increase of serum triglyceride concentration. At the end of infusion, mean serum triglyceride concentration was significantly lower with SMOF (p < 0.05). Triglyceride half-life was significantly shorter for SMOF than for Lipovenoes (p < 0.001). Infusion of SMOF was apparently associated with higher glycerol concentration (NS). Routine laboratory parameters, vital signs and local tolerance showed no evidence of infusion-related abnormalities. Conclusion: SMOF was eliminated significantly faster than the standard lipid emulsion. This is of potential benefit in patients with limited triglyceride elimination capacity. The safety evaluation revealed a good systemic and local tolerance of SMOF.

100 Deals associated with Fresenius Kabi

Login to view more data

100 Translational Medicine associated with Fresenius Kabi

Login to view more data